The newly MDR-certified (NB 2862), next-generation AMRA® Profiler 4 device, a unique approach for quantifying fat and muscles, was evaluated in the study to be helpful in liver disease research, representing a crucial step forward for the use of muscle composition assessments in the field
Read MoreThe recent study – part of the CoMorMent initiative – provides new evidence for body composition measurements as an important tool for examining adverse treatment effects associated with the use of antidepressants
Read MoreThe recently published primer summarizes contemporary evidence indicating that muscle composition changes associated with GLP-1-based therapies appear to be adaptive
Read MoreResearchers from AMRA will present an abstract at the 60th annual European Association for the Study of Diabetes Meeting that emphasizes the link between adverse muscle composition and all-cause mortality in Type II Diabetes
Read MoreAMRA Medical continues to set the standard in MRI-based body composition analysis with their recently obtained EU MDR certificate (NB 2862) for the next-generation AMRA® Profiler 4
Read MoreAMRA expands footprint in kidney disease research with updated results from a study exploring various biomarkers’ potential in characterizing muscle composition’s role in chronic kidney disease progression and identifying at-risk patients
Read More
